DRG Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CHF for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.

DRG Epidemiology’s CHF will answer the following questions:

  • Of all people diagnosed with CHF, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CHF over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In total, DRG Epidemiology forecasts seven CHF patient populations, as follows:

  • Diagnosed prevalent cases.
  • Diagnosed drug-treated prevalent cases.
  • Diagnosed non-drug-treated prevalent cases.
  • Diagnosed NYHA class I prevalent cases.
  • Diagnosed NYHA class II prevalent cases.
  • Diagnosed NYHA class III prevalent cases.
  • Diagnosed NYHA class IV prevalent cases.

Note: Coverage may vary by country.

Table of contents

  • Chronic Heart Failure - Epidemiology - Americas

Author(s): Sunali D. Goonesekera, SM

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.

Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.


Related Reports

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is categorized into acute or chronic, and both settings are the focus of this report. While much progress has been made in the pharmacological management of HF, it mainly re...

View Details

Heart Failure - Geographic Focus: China - Heart Failure | China In-Depth | China

Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Preserved Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophys...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF)...

View Details